Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Total Non-Current Liabilities (2016 - 2025)

Northwest Biotherapeutics' Total Non-Current Liabilities history spans 16 years, with the latest figure at $37.2 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $37.2 million for Q4 2025, down 0.73% from a year ago — trailing twelve months through Dec 2025 was $37.2 million (down 0.73% YoY), and the annual figure for FY2025 was $37.2 million, down 0.73%.
  • Total Non-Current Liabilities for Q4 2025 was $37.2 million at Northwest Biotherapeutics, down from $38.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $38.0 million in Q3 2025 to a low of $10.1 million in Q3 2022.
  • The 5-year median for Total Non-Current Liabilities is $23.2 million (2021), against an average of $25.1 million.
  • The sharpest move saw Total Non-Current Liabilities surged 392.71% in 2021, then crashed 65.9% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $30.4 million in 2021, then crashed by 65.9% to $10.4 million in 2022, then surged by 186.81% to $29.7 million in 2023, then rose by 25.97% to $37.4 million in 2024, then decreased by 0.73% to $37.2 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $37.2 million, $38.0 million, and $32.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.